NEW YORK, March 30, 2017 /PRNewswire/ --
Stock-Callers.com navigates the Medical Instruments and Supplies space,which is involved in the research, development, and production of non-electronic medical, surgical, dental, and veterinary instruments and apparatus. Equities in today's lineup are: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Co. (NYSE: BDX),
Irvine, California headquartered Endologix Inc.'s shares declined 0.21%, closing Wednesday's trading session at $7.07. The stock recorded a trading volume of 814,017 shares. Shares of the Company have advanced 6.88% in the last month, 34.06% over the previous three months, and 23.51% since the start of this year. The stock is trading 5.63% above its 50-day moving average. Additionally, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 58.30. See our free and comprehensive research report on ELGX at:
On Wednesday, shares in Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co. (BDX) recorded a trading volume of 454,533 shares. The stock fell 0.03%, ending the day at $183.87. The Company's shares have advanced 0.85% in the past month, 10.50% in the previous three months, and 11.51% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.39% and 6.43%, respectively. Furthermore, shares of Becton, Dickinson and Co., which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 57.23.
On March 01st, 2017, BDX announced that it was awarded a contract worth up to $100 million with the Defense Health Agency (DHA) under the US Department of Defense for its Pyxis™ ES System. Under the purchase agreement, BDX will provide its enterprise-wide medication dispensing technology platform across DHA's 115 military inpatient health facilities and military inpatient pharmacies. BDX free research report PDF is just a click away at:
Ewing, New Jersey headquartered Antares Pharma Inc.'s stock finished the day 0.72% lower at $2.74 with a total trading volume of 894,350 shares. The Company's shares have advanced 11.38% in the last one month, 16.60% in the previous three months, and 17.60% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 13.72% and 54.96%, respectively. Additionally, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 60.54.
On March 14th, 2017, Antares Pharma reported operating progress and financial results for Q4 2016 and full year ended December 31st, 2016. The Company reported revenue of $14.2 million for Q4, and $52.2 million for the full year. Net loss per share was $0.03 and $0.16 for Q4 and full year 2016, respectively. Sign up for your complimentary report on ATRS at:
C. R. Bard
Shares in Murray Hill, New Jersey headquartered C. R. Bard Inc. ended yesterday's session 0.32% lower at $249.68. The stock recorded a trading volume of 359,420 shares. The Company's shares have advanced 1.81% in the last one month, 11.83% over the previous three months, and 11.26% since the start of this year. The stock is trading 3.02% and 9.96% above its 50-day and 200-day moving averages, respectively. Moreover, shares of C. R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 59.68. Register for free on Stock-Callers.com and download the latest research report on BCR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All